Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049840 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL19544557 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL21049848 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL12092183 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL19316994 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL12505785 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL31618958 | 1.00 | TSHR (0.70) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL3489828 | 0.96 | — | — | |
| SCHEMBL26689876 | 0.89 | TSHR (0.58) | TSHRHSD17B10CYP2D6MAPTCYP1A2 | |
| SCHEMBL30302153 | 0.88 | TSHR (0.92) | TSHRHSD17B10CYP2D6MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | claimed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | claimed |
| US-20240316249-A1 | INJECTION FORMULATION COMPOSITION FOR USE AS FILLER OR DRUG CARRIER THROUGH CLICK CHEMISTRY REACTION | Ajou University Industry-Academic Corporation Foundation (KR) | 2024-09-26 | — | — | US | claimed |
| CN-118546380-A | Biodegradable polymer, preparation method and application thereof, and medical filling material | 上海发微医用材料有限公司 | 2024-08-27 | — | — | CN | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | claimed |
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | NAUTILUS SUBSIDIARY INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20250349136-A1 | METHODS AND SYSTEMS FOR COMPUTATIONAL DECODING OF BIOLOGICAL, CHEMICAL, AND PHYSICAL ENTITIES | NAUTILUS SUBSIDIARY INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3448417-B1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | TSHR 4141/4885HSD17B10 4296/4885CYP2D6 4305/4885 |
| US-20260116914-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | SPPL2B, SNAP29, SPPL2A | TSHR 1914/4885HSD17B10 4672/4885CYP2D6 4558/4885 |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | TSHR 4077/4885HSD17B10 1100/4885CYP2D6 1671/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | TSHR 4141/4885HSD17B10 4296/4885CYP2D6 4305/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | TSHR 4141/4885HSD17B10 4296/4885CYP2D6 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.